154 related articles for article (PubMed ID: 1564165)
21. Serum aminoterminal type III procollagen peptide and the 7S domain of type IV collagen in patients with alcohol abuse. Relation to ultrastructural fibrosis in the acinar zone 3 and to serum hyaluronan.
Bentsen KD; Horn T; Risteli J; Risteli L; Engström-Laurent A; Hørslev-Petersen K; Lorenzen I
Liver; 1987 Dec; 7(6):339-46. PubMed ID: 3437796
[TBL] [Abstract][Full Text] [Related]
22. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.
Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S
Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812
[TBL] [Abstract][Full Text] [Related]
23. Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis.
Osada K; Seishima M; Mori S; Seishima M; Takemura M; Noma A
Br J Dermatol; 1994 Nov; 131(5):655-9. PubMed ID: 7999596
[TBL] [Abstract][Full Text] [Related]
24. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection.
Rokhsar C; Rabhan N; Cohen SR
J Am Acad Dermatol; 2006 Feb; 54(2):361-2. PubMed ID: 16443079
[No Abstract] [Full Text] [Related]
25. The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
Lynch M; Higgins E; McCormick PA; Kirby B; Nolan N; Rogers S; Lally A; Vellinga A; Omar H; Collins P
JAMA Dermatol; 2014 Aug; 150(8):856-62. PubMed ID: 24964792
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate in the treatment of psoriasis at the National Skin Centre, Singapore.
Lim JT; Tham SN
Ann Acad Med Singap; 1994 Nov; 23(6):848-51. PubMed ID: 7741497
[TBL] [Abstract][Full Text] [Related]
27. Soluble biomarkers may differentiate psoriasis from psoriatic arthritis.
Chandran V
J Rheumatol Suppl; 2012 Jul; 89():65-6. PubMed ID: 22751596
[TBL] [Abstract][Full Text] [Related]
28. Splanchnic and renal extraction of circulating type III procollagen aminoterminal propeptide in patients with normal liver function and in patients with alcoholic cirrhosis.
Bentsen KD; Henriksen JH; Bendtsen F; Hørslev-Petersen K; Lorenzen I
Hepatology; 1990 Jun; 11(6):957-63. PubMed ID: 2365293
[TBL] [Abstract][Full Text] [Related]
29. Effects on fibrogenesis markers of rheumatoid arthritis therapy with methotrexate.
Biasi D; Bambara LM; Carletto A; Casaril M; Capra F; Caramaschi P; Corrocher R
J Rheumatol; 1996 Mar; 23(3):453-4. PubMed ID: 8832981
[TBL] [Abstract][Full Text] [Related]
30. Bone loss in patients with psoriatic arthritis and psoriasis vulgaris.
Zinnuroğlu M; Dinçel AS; Oztaş MO; Kosova F; Sepici V
Rheumatol Int; 2007 Aug; 27(10):993-4. PubMed ID: 17468872
[No Abstract] [Full Text] [Related]
31. Have methotrexate-induced liver fibrosis and cirrhosis become rare? A matter for reappraisal of routine liver biopsies.
Zachariae H
Dermatology; 2005; 211(4):307-8. PubMed ID: 16286736
[No Abstract] [Full Text] [Related]
32. Serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen and laminin P1 in Duchenne muscular dystrophy.
von Moers A; Danne T; Möller P; Scheffner D
Acta Paediatr; 1997 Apr; 86(4):377-80. PubMed ID: 9174223
[TBL] [Abstract][Full Text] [Related]
33. Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?
Lindsay K; Gough A
Rheumatology (Oxford); 2008 Jul; 47(7):939-41. PubMed ID: 18474510
[No Abstract] [Full Text] [Related]
34. Methotrexate for psoriasis in the era of biological therapy.
Warren RB; Chalmers RJ; Griffiths CE; Menter A
Clin Exp Dermatol; 2008 Aug; 33(5):551-4. PubMed ID: 18801095
[TBL] [Abstract][Full Text] [Related]
35. Total cholesterol, lipoprotein, and triglyceride levels in tumor necrosis factor inhibitor-treated patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis.
Wu JJ; Rowan CG; Bebchuk JD; Anthony MS
Int J Dermatol; 2015 Oct; 54(10):e442-5. PubMed ID: 26234307
[No Abstract] [Full Text] [Related]
36. Use of amino terminal type III procollagen peptide (P3NP) assay in methotrexate therapy for psoriasis.
Khan S; Subedi D; Chowdhury MM
Postgrad Med J; 2006 May; 82(967):353-4. PubMed ID: 16679477
[TBL] [Abstract][Full Text] [Related]
37. Serum concentrations of laminin and aminoterminal propeptide of type III procollagen in relation to the portal venous pressure of fibrotic liver diseases.
Gressner AM; Tittor W; Negwer A; Pick-Kober KH
Clin Chim Acta; 1986 Dec; 161(3):249-58. PubMed ID: 3802532
[TBL] [Abstract][Full Text] [Related]
38. The blue glass and the predictive value of serum amino-terminal propeptide of type III procollagen as a marker of liver fibrosis.
Rojkind M
Hepatology; 1984; 4(5):977-8. PubMed ID: 6479861
[No Abstract] [Full Text] [Related]
39. Cryptogenic chronic active liver disease. Evaluation of serum aminoterminal peptide of type III procollagen as a marker of histological activity.
Diodati G; Bonetti P; Plebani M; Giacomini A; Rugge M; Realdi G; Burlina A
Ric Clin Lab; 1990; 20(4):253-9. PubMed ID: 2075377
[TBL] [Abstract][Full Text] [Related]
40. Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis.
Wu JJ; Rowan CG; Bebchuk JD; Anthony MS
J Am Acad Dermatol; 2015 May; 72(5):917-9. PubMed ID: 25748312
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
